Needham Reiterates Buy on BioCryst Pharma, Maintains $12 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Serge Belanger has reiterated a 'Buy' rating on BioCryst Pharma (NASDAQ:BCRX) and maintained a price target of $12.
November 06, 2023 | 11:34 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BioCryst Pharma's stock rating has been reiterated as 'Buy' by Needham analyst Serge Belanger, with a maintained price target of $12.
The reiteration of a 'Buy' rating by a respected analyst like Serge Belanger is a positive signal for BioCryst Pharma. The maintained price target of $12 also indicates that the analyst believes the stock has potential for growth. This could lead to increased investor confidence and potentially a rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100